1. Germany Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
co.don AG

co.don AG

CNW.DE
co.don AGDE flagDeutsche Börse
0.25
EUR
- -
- -
6.55MMarket Cap
co.don AG
CNW.DE
(Deutsche Börse)

Recent

price

0.25

P/E

ratio

- -

div

yld

- -

ROIC.AI

2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
FRC
- -
0.17
0.22
0.25
0.28
0.56
0.44
0.56
0.56
0.55
0.61
0.58
0.48
0.55
0.36
- -
Revenue per Share
- -
-0.21
-0.13
-0.24
-0.19
-0.25
-0.39
-0.42
-0.31
-0.31
-0.4
-0.6
-0.53
-1.01
-0.8
- -
Basic EPS, GAAP
- -
- -
- -
-0.17
-0.24
-0.34
-0.38
-0.24
-0.27
-0.32
-0.41
-0.85
-1.33
-1.08
-0.58
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-2.41
-2.55
-2.79
-2.57
0.6
0.59
0.22
0.19
0.13
-0.27
-0.53
-0.99
-1.59
-0.82
- -
Book Value per Share
- -
0.64
0.48
0.26
0.29
0.56
0.63
0.25
0.52
0.68
0.29
1.48
1.03
0.84
1.17
- -
Tangible Book Value per Share
- -
7
7
7
8
4
6
6
8
9
9
11
12
12
17
- -
Basic Weighted Avg Shares
- -
1
2
2
2
2
3
4
4
5
6
6
6
7
6
10
Sales/Revenue/Turnover
- -
-138.51
-69.94
-97.6
-66.9
-43.87
-88.41
-73.52
-55.34
-56.21
-65.17
-101.79
-151.41
-137.79
-161.7
-85.96
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
Depreciation Expense
- -
-1
-1
-2
-1
-1
-2
-3
-2
-3
-4
-7
-6
-13
-14
-9
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-120.63
-60.65
-95.72
-66.81
-43.61
-88.41
-74.1
-55.7
-56.35
-65.2
-103.98
-110.91
-184.2
-222.51
-95.09
Profit Margin (%)
5
4
3
2
2
2
4
2
4
5
1
11
7
3
8
6
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
9
9
5
6
LT Debt
6
4
4
2
2
2
4
2
4
6
3
16
13
12
21
18
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
-77.66
-105.94
-169.13
-212.53
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
66.34%
105.52%
-14.78%
Free Cash Flow
29.55%
31.65%
-16.53%
Net Income, GAAP
33.76%
30.79%
-32.79%
Sales/Revenue/Turnover
16.99%
14.37%
57.28%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
6
2021
- -
- -
- -
- -
10
2022
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
-0.8
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Similar Companies
Basilea Pharmaceutica AG (BPMUF)
Abcam plc (ABCM)
Uni-Bio Science Group Limited (0690.HK)
GlobeImmune, Inc. (GBIM)
Vericel Corporation (VCEL)
Scancell Holdings plc (SCLP.L)
Business
co.don AG co.don AG engages in no significant operations. Previously, the company developed, produced and marketed autologous cell therapies for the regenerative treatment of articular cartilage defects in joints, including its flagship products Spherox and Chondrosphere, which utilize patients' own cartilage cells (autologous chondrocytes) in spheroid technology for minimally invasive repair of knee cartilage damage following trauma or degeneration; these prescription-only medicinal products were authorized by the European Medicines Agency for distribution across Europe since 2017 and used in over 200 clinics with more than 17,000 patients treated. Founded in 1993 and headquartered in Teltow, Germany, co.don AG operated manufacturing facilities meeting EU-GMP standards in Teltow and Leipzig, serving orthopedic surgeons and hospitals primarily in Germany and the European Union through subsidiaries and partnerships in countries including the Netherlands, Austria and the United Kingdom. In January 2023, ReLive Biotechnologies Ltd acquired 100% of co.don AG's core assets, including global patent rights to Spherox and Chondrosphere, manufacturing facilities and quality systems, via its German subsidiary CO.DON GmbH, which took over all business operations and consolidated production to the Teltow site while maintaining administration in Leipzig; CO.DON GmbH, now a ReLive company, continues development and commercialization efforts, including participation in an EU-funded project for 3D bioprinting in tissue regeneration as of February 2025.